Diabetes and COVID-19 testing, positivity, and mortality: A population-wide study in Northern Italy.


Journal

Diabetes research and clinical practice
ISSN: 1872-8227
Titre abrégé: Diabetes Res Clin Pract
Pays: Ireland
ID NLM: 8508335

Informations de publication

Date de publication:
Sep 2022
Historique:
received: 29 04 2022
revised: 18 08 2022
accepted: 22 08 2022
pubmed: 29 8 2022
medline: 6 10 2022
entrez: 28 8 2022
Statut: ppublish

Résumé

To assess if patients with type 2 diabetes mellitus (DM2) are: a) at excess risk of undergoing testing, contracting, and dying from SARS-CoV-2 infection compared to the general population; b) whether cardiovascular diseases (CAVDs) contribute to COVID-19-related death; and c) what is the effect of DM2 duration and control on COVID-19-related death. This population-based study involved all 449,440 adult residents of the Reggio Emilia province, Italy. DM2 patients were divided in groups by COVID testing, presence of CAVDs and COVID death. Several mediation analyses were performed. Patients with DM2 had an increased likelihood of being tested (Odds ratio, OR 1.27 95 %CI 1.23-1.30), testing positive (OR 1.21 95 %CI 1.16-1.26) and dying from COVID-19 (OR 1.75 95 %CI 1.54-2.00). COVID-19-related death was almost three times higher among obese vs non-obese patients with DM2 (OR 4.3 vs 1.6, respectively). For COVID-19 death, CAVDs mediated a) just 5.1 % of the total effect of DM2, b) 40 % of the effect of DM2 duration, and c) did not mediate the effect of glycemic control. For COVID-19-related deaths in DM2 patients, the effect is mostly direct, obesity amplifies it, DM2 control and duration are important predictors, while CAVDs only slightly mediates it.

Identifiants

pubmed: 36030900
pii: S0168-8227(22)00865-8
doi: 10.1016/j.diabres.2022.110051
pmc: PMC9417741
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

110051

Informations de copyright

Copyright © 2022 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Références

Diabetes Care. 2020 Oct;43(10):e118-e119
pubmed: 32647055
Diabetes Obes Metab. 2021 Aug;23(8):1995-2000
pubmed: 33822446
Diabetologia. 2021 Jul;64(7):1480-1491
pubmed: 33907860
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
Front Endocrinol (Lausanne). 2020 Sep 17;11:582870
pubmed: 33042029
Diabetes Res Clin Pract. 2014 Jan;103(1):79-87
pubmed: 24369984
Diabetologia. 2014 Dec;57(12):2465-74
pubmed: 25226881
Front Endocrinol (Lausanne). 2021 Jun 17;12:649525
pubmed: 34220706
Diabetes Res Clin Pract. 2021 Apr;174:108750
pubmed: 33722703
Int J Infect Dis. 2020 May;94:91-95
pubmed: 32173574
Prev Chronic Dis. 2021 Jul 01;18:E66
pubmed: 34197283
Lancet Respir Med. 2020 May;8(5):475-481
pubmed: 32105632
Diabetol Metab Syndr. 2020 Aug 31;12:75
pubmed: 32874207
Lancet Diabetes Endocrinol. 2016 Feb;4(2):148-58
pubmed: 26656292
Intensive Care Med. 2020 Sep;46(9):1784-1786
pubmed: 32601834
J Diabetes. 2021 Jul;13(7):585-595
pubmed: 33655669
J Diabetes. 2022 Feb;14(2):144-157
pubmed: 34939735
Georgian Med News. 2020 Apr;(301):105-112
pubmed: 32535573
Int J Epidemiol. 2013 Oct;42(5):1511-9
pubmed: 24019424
Nat Commun. 2020 Nov 12;11(1):5749
pubmed: 33184277
BMJ Open. 2021 Oct 25;11(10):e052777
pubmed: 34697120
Diabetes Metab Syndr. 2020 Sep - Oct;14(5):765-766
pubmed: 32512520
Nature. 2020 Aug;584(7821):430-436
pubmed: 32640463
Diabetol Metab Syndr. 2021 Sep 7;13(1):95
pubmed: 34493317
Clin Infect Dis. 2021 Oct 5;73(7):e2005-e2015
pubmed: 32860699
Rev Endocr Metab Disord. 2021 Jun;22(2):275-296
pubmed: 33616801
Int J Infect Dis. 2020 Oct;99:47-56
pubmed: 32721533
Eur J Epidemiol. 2022 Feb;37(2):157-165
pubmed: 35083602
Diabetes Res Clin Pract. 2021 Oct;180:109021
pubmed: 34437941
Lancet Reg Health Eur. 2021 May;4:100105
pubmed: 33969336
Lancet Diabetes Endocrinol. 2020 Oct;8(10):823-833
pubmed: 32798471

Auteurs

Olivera Djuric (O)

Epidemiology Unit, Azienda USL - IRCCS di Reggio Emilia, 42122 Reggio Emilia, Italy; Centre for Environmental, Nutritional and Genetic Epidemiology (CREAGEN), Section of Public Health, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, 41125 Modena, Italy. Electronic address: olivera.duric@ausl.re.it.

Marta Ottone (M)

Epidemiology Unit, Azienda USL - IRCCS di Reggio Emilia, 42122 Reggio Emilia, Italy.

Massimo Vicentini (M)

Epidemiology Unit, Azienda USL - IRCCS di Reggio Emilia, 42122 Reggio Emilia, Italy.

Francesco Venturelli (F)

Public Health Unit, Azienda USL - IRCCS di Reggio Emilia, 42122 Reggio Emilia, Italy.

Annamaria Pezzarossi (A)

Epidemiology Unit, Azienda USL - IRCCS di Reggio Emilia, 42122 Reggio Emilia, Italy.

Valeria Manicardi (V)

Medical Diabetologist Association Coordinator, Diabetologist, Salus Hospital, 42122 Reggio Emilia, Italy.

Marina Greci (M)

Primary Health Care Department, Azienda USL - IRCCS di Reggio Emilia, 42122 Reggio Emilia, Italy.

Paolo Giorgi Rossi (P)

Epidemiology Unit, Azienda USL - IRCCS di Reggio Emilia, 42122 Reggio Emilia, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH